{"name":"Celsius Therapeutics, Inc.","slug":"celsius-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"Celsius Therapeutics is a biotechnology company focused on developing novel therapies for cancer and other diseases by leveraging its proprietary single-cell genomics platform. The company's lead candidate, CEL383, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPU0lnZWxoOFNuUmN0VEZzb3FOVUNIRzNHYW1WcW4tMlJaUVV4WWNoOTQwSmtxOFJvVTE3OVQ2NHMzMHpSM3dwX1FUcUVhb3p3Mi1YY0tiLUNBZTV5ODZUa0ZWemxPZURydDlpM2h6aUQ2eFgtbHFrSVNNdTJFVVB0NEYxNnlWVTlmYl9MTUd0WFNsTlB5QUVHN3Z5ZktCVjg?oc=5","date":"2025-10-30","type":"trial","source":"Market Data Forecast","summary":"Artificial Intelligence in Drug Discovery Market Size, 2033 - Market Data Forecast","headline":"Artificial Intelligence in Drug Discovery Market Size, 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOSVdBU2dOSUNyX3VZMmhmWlVNcFp0UjZNWlVVblB1MnlGLWdfR29PWVoyZkROTndFZW4zcV9uQThzMVlZVjg3Q3NOZ1cyUFZfZVR1cGtnczhmcEQ2M3NUUFF1WHRaLU1UZnNNbVFIbzh6TFhacFVBZ3I1VGRSenl3bQ?oc=5","date":"2025-03-31","type":"pipeline","source":"Fierce Biotech","summary":"The top 10 pharma R&D budgets for 2024 - Fierce Biotech","headline":"The top 10 pharma R&D budgets for 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPMng4bVlqTnlGakxZdTA2OE1WY2txeFNjVmYwM0RmOGUyeVBDa3JBUUdxVHNXWC1HaTlVeGVzLThYS0pQblVlbFZfeXAwN0RKclI5WUFEMTR6OTh6R0puN0hqTmlqa01YSXlKVVM5Q1YzSXpMX1RQRjE1SjNFbVhjUGRoUk1oempIM21tSktuNFRYQkJ2MWZEekJRekRCb3Z3RnpyUGRwTzBtYmRjOHNuNWw0dzg?oc=5","date":"2024-12-19","type":"deal","source":"Intellizence","summary":"Mergers & Acquisitions by Top Biotechnology Companies – 2024 - Intellizence","headline":"Mergers & Acquisitions by Top Biotechnology Companies – 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFBhVklPNkxqa0VmZk5MUnFKSDZvX2pqaDJyOXBDVTJ0OXFVRVVIeGs0Nnc3ZTZJSEZhY3dneXBzM05IOS1GWEhtR0FOcXM4X0FHLWVKNi1UU2Y3c2kzTnc1ZUt0WGtIZEQyQkVNUXZsSnFIVFJIRm9uYg?oc=5","date":"2024-07-30","type":"pipeline","source":"Labiotech.eu","summary":"Why is the immunology and inflammation market suddenly attracting a wave of investment? - Labiotech.eu","headline":"Why is the immunology and inflammation market suddenly attracting a wave of investment?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNN0NXRUlVSzdPS2ZfbWpfZDNiUE9IRl95Q1h5bWFEZHF0VXpfTnVzV3MtUUUzdDBRek1IUlItNjJ1QldhU2VjMWhybVhtRmlpTmUtakQ2bUl3QzZ4dkRxajNoWXU3RXFlYXVjdHRERnhBSElYZjRnNTRwTHM1dU9YdjIwTXF2V0d6WnZPNg?oc=5","date":"2024-06-28","type":"deal","source":"Pharmaceutical Technology","summary":"AbbVie acquires biotech Celsius Therapeutics for $250m - Pharmaceutical Technology","headline":"AbbVie acquires biotech Celsius Therapeutics for $250m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQdE81dGNMd1JrdFN1aGVKRXViQXgxbkh5bTNIeWdSeHhyMGZSRXRzdFdhczRtdmZRQlM2dkRsU1drWmQzU2J0enNoSGdQelY2MnFTZVFpSnN2SGlzVXRhVVQxQXliY292Y0UwUEpiQnl6endkclBVaVg1V3FsRW9vRzdJeVNnc2pGc0h3QmlVSVRUY1BHNW9XcC1UYXlrbUlhektkQlZRcnF2TlpOR3FrMTBxeTdHVDE3NDk4eQ?oc=5","date":"2024-06-28","type":"deal","source":"BioPharm International","summary":"AbbVie Acquires Celsius Therapeutics, Gains Anti-Inflammatory Disease Antibody - BioPharm International","headline":"AbbVie Acquires Celsius Therapeutics, Gains Anti-Inflammatory Disease Antibody","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQNnh0b3VqdXVIal8zdzJvVy1pX1NZV2pXR1NlcEVuU1JMQUY3QVllTl9lSXd2OUZGRlJJZlZFUUlDeVIwSWhOQ1VndFhrLUMtSGc3aTFlTjJFNlJGdHNIWHoxcFhQdHpjV3BkYUE4b1JMSHEzZXAydktaRERUSDJfdGlYazVqVGlTb0dnY1J0aVVPRTk5Qi13?oc=5","date":"2024-06-27","type":"deal","source":"PR Newswire","summary":"AbbVie Acquires Celsius Therapeutics - PR Newswire","headline":"AbbVie Acquires Celsius Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQdWdaaGhHTGlQQlM2aEdianduMG1ENGM1TXlkb01WeVZjOEVHMmhOeThaVnFHT3ltTC13UFlpcnZaYVdrRm52cmZMMTU2VjI3b3hyRUNiN1haWHVBUjVsWV9lSEJ5cm1SVTVqQnBMME9tRUcxUHk5NnBQYmEzcHNJTVg5M2hrU1Y1VjN2WA?oc=5","date":"2024-06-27","type":"deal","source":"BioPharma Dive","summary":"AbbVie expands its IBD prospects with $250M Celsius deal - BioPharma Dive","headline":"AbbVie expands its IBD prospects with $250M Celsius deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNUF9BTE9EeUQzbmJDb0F2ZXE1bzRiZW1TaFEyRTFnNDRUb1NFeVhkTURZbWtHaDRQNWlvcloxazZMMnc3Y2licXdOUXhGU1p1b0EzZUhCVmtTZTRmSFpiWDEwT0U0S1lVSUpGeUduWnNFTzhCcUJkR1JxTjlUb3c3dWRQcURjeDlvUG5leWMtU3FhV2loanhlREpZTQ?oc=5","date":"2024-06-27","type":"deal","source":"The Business Journals","summary":"AbbVie pays $250 million to acquire Celsius Therapeutics - The Business Journals","headline":"AbbVie pays $250 million to acquire Celsius Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE1udlowOC1mQlU0QWFhOEQ2cktDOEJkRjdRalljNjJzci1fcVptUFVhSVRTR3hVQUhxUzhhd3dNdURna0JYSmtabkdfbWVCNHdLTFQ1Y2xHZDMtSHJVbkU1TFVzejRQTnpRY0hMc3BlMG05eVN5N24ya2J6cDB1Z0E?oc=5","date":"2024-06-27","type":"deal","source":"The Boston Globe","summary":"AbbVie to buy Cambridge biotech Celsius for $250 million - The Boston Globe","headline":"AbbVie to buy Cambridge biotech Celsius for $250 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9tcXNrUXZQZXZXeWxtMTBCM0xYN0t2OFF6bmUtaEJZcDNpMERJYkxMdkxXQ2M1SXdHN2JyZWMtdnFZN1ktYWE4REhCY09wbUNxbXlrbjBQcVZkemQzdFVQeHE1bnVaeWtnTTAwU0EtRzVoX2YzRW9rNDBfVQ?oc=5","date":"2022-09-06","type":"pipeline","source":"Pharma Voice","summary":"Innovators: Jeanne Magram - Pharma Voice","headline":"Innovators: Jeanne Magram","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxPVDBmdkNsa1pIMG1fTHE5RE9XdzhrRk1tS3lScDlRTExWcjVGa2NUMGpKNnZkTkNQMUdyUUdaWjR6cXc0b1NvQWdmQmVYaVFlVjJWX0ZNXzRIZ3RIZG10Z3Y2Yk5RSmRsbmp5MzZHTS11M0l6YzZmTVpCRjRQVDNHSXRUZkFTcU9CTTVGUXhUQ05GVkZaVnZmWWtMVnFmQ2x1X3kwT2NrUjNIeWFhVTRpUDU3TVFhSTdnT3NCM2RCT2c5eHViNndQTUh3dU1fRXdEME1RRGFhYw?oc=5","date":"2022-03-24","type":"pipeline","source":"Business Wire","summary":"Celsius Therapeutics Highlights Recent Accomplishments and Key Initiatives for 2022 - Business Wire","headline":"Celsius Therapeutics Highlights Recent Accomplishments and Key Initiatives for 2022","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}